Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non- progressing cancers

Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non- progressing cancers

361

No coordinating investigator defined.

No involved investigator sites defined.

We will obtain cDNAs of the up-regulated proteins previously published: CD30 ligand, endostatin, HSP90alpha, MIP-4, pleiotrophin, PFKCI, and YES (a tyrosine kinase oncogene). Based on our previous studies, a panel consisting of thirteen protein biomarkers will be used for determining presence or absence of autoantibodies in serum specimen. The 13-protein marker panel consisting of purified full-length recombinant proteins are c-myc, cyclin A, cyclin B1, cyclin D1, CDK2, survivin, CD30 ligand, endostatin, HSP90alpha, MIP-4, pleiotrophin, PRKCI, and YES.
Glycomics
Lung and Upper Aerodigestive Cancers Research Group

We hypothesize that our novel Biomarker Panel of Auto-antibodies can distinguish aggressive, symptom diagnosed lung cancer from non-aggressive, screen-detected lung cancer.

Specific Aim 1. Develop a novel biomarker panel based on our auto-antibody publication and our development of an Immunoruler using auto-antibodies to glycosylated proteins using synthetic glycans printed on glass microarray technology. Specific Aim 2. Test the autoantibody panels on CT-scan screen-detected lung cancers including both indolent and aggressive cancers, and validate with thoracic surgery lung cancer cases stratified by no recurrence within three years “indolent” and recurrent within three years “aggressive.” Each lung cancer case will be matched to a control with normal CT scans by smoking, gender, and age.
development of an Immunoruler using auto-antibodies to glycosylated proteins using synthetic glycans printed on glass microarray technology. Each sample will be assessed in triplicates, and the average value at 490 nm will be used for data analysis. During the 02 year we will be focusing our efforts at completing the assays and data analysis.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place October 15–16, 2015 in Bethesda, Maryland.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.

Announcement 04/08/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held October 15-16, 2015 on the NCI campus. More information will be available later this summer.